Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q7RTZ2
UPID:
U17L1_HUMAN
Alternative names:
Deubiquitinating enzyme 17-like protein 1; Ubiquitin thioesterase 17-like protein 1; Ubiquitin-specific-processing protease 17-like protein 1
Alternative UPACC:
Q7RTZ2
Background:
Ubiquitin carboxyl-terminal hydrolase 17-like protein 1, also known as Deubiquitinating enzyme 17-like protein 1, plays a pivotal role in cellular processes by removing ubiquitin from specific proteins. This action is crucial for regulating cell proliferation, cell cycle progression, apoptosis, cell migration, and the cellular response to viral infection.
Therapeutic significance:
Understanding the role of Ubiquitin carboxyl-terminal hydrolase 17-like protein 1 could open doors to potential therapeutic strategies.